Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
OBJECTIVE: Autologous stem cell transplantation (ASCT) has improved progression‐free survival (PFS) and overall survival in eligible patients with newly diagnosed multiple myeloma (NDMM); however, relapse occurs. Maintenance therapy with lenalidomide (Len‐Mt) extends survival and delays relapse and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590122/ https://www.ncbi.nlm.nih.gov/pubmed/32705720 http://dx.doi.org/10.1111/ejh.13497 |
_version_ | 1783600735238225920 |
---|---|
author | Uyl‐de Groot, Carin A. Ramsden, Rachel Lee, Dawn Boersma, Janneke Zweegman, Sonja Dhanasiri, Sujith |
author_facet | Uyl‐de Groot, Carin A. Ramsden, Rachel Lee, Dawn Boersma, Janneke Zweegman, Sonja Dhanasiri, Sujith |
author_sort | Uyl‐de Groot, Carin A. |
collection | PubMed |
description | OBJECTIVE: Autologous stem cell transplantation (ASCT) has improved progression‐free survival (PFS) and overall survival in eligible patients with newly diagnosed multiple myeloma (NDMM); however, relapse occurs. Maintenance therapy with lenalidomide (Len‐Mt) extends survival and delays relapse and the subsequent initiation of costly second‐line regimens. Here, we report the cost‐effectiveness of Len‐Mt following ASCT from a Dutch healthcare service perspective. METHODS: A partitioned survival model was developed to assess the lifetime costs and benefits for patients with NDMM. Efficacy was taken from a pooled meta‐analysis of clinical trial data. Costs and subsequent therapy data were taken from sources appropriate for the Dutch market. RESULTS: Lenalidomide produced a quality‐adjusted life year gain of 2.46 and a life year gain of 2.79 vs no maintenance treatment. The cost of lenalidomide was partially offset by savings of EUR 77 462 in subsequent treatment costs. The incremental cost‐effectiveness ratio of Len‐Mt vs no maintenance treatment was EUR 30 143. Key model drivers included subsequent therapies, dosing schedule, and time horizon. CONCLUSION: Lenalidomide is cost‐effective after ASCT vs no maintenance therapy in the Netherlands. By extending PFS, lenalidomide delays the cost burdens associated with relapse and subsequent treatment lines. |
format | Online Article Text |
id | pubmed-7590122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75901222020-10-30 Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment Uyl‐de Groot, Carin A. Ramsden, Rachel Lee, Dawn Boersma, Janneke Zweegman, Sonja Dhanasiri, Sujith Eur J Haematol Original Articles OBJECTIVE: Autologous stem cell transplantation (ASCT) has improved progression‐free survival (PFS) and overall survival in eligible patients with newly diagnosed multiple myeloma (NDMM); however, relapse occurs. Maintenance therapy with lenalidomide (Len‐Mt) extends survival and delays relapse and the subsequent initiation of costly second‐line regimens. Here, we report the cost‐effectiveness of Len‐Mt following ASCT from a Dutch healthcare service perspective. METHODS: A partitioned survival model was developed to assess the lifetime costs and benefits for patients with NDMM. Efficacy was taken from a pooled meta‐analysis of clinical trial data. Costs and subsequent therapy data were taken from sources appropriate for the Dutch market. RESULTS: Lenalidomide produced a quality‐adjusted life year gain of 2.46 and a life year gain of 2.79 vs no maintenance treatment. The cost of lenalidomide was partially offset by savings of EUR 77 462 in subsequent treatment costs. The incremental cost‐effectiveness ratio of Len‐Mt vs no maintenance treatment was EUR 30 143. Key model drivers included subsequent therapies, dosing schedule, and time horizon. CONCLUSION: Lenalidomide is cost‐effective after ASCT vs no maintenance therapy in the Netherlands. By extending PFS, lenalidomide delays the cost burdens associated with relapse and subsequent treatment lines. John Wiley and Sons Inc. 2020-09-12 2020-11 /pmc/articles/PMC7590122/ /pubmed/32705720 http://dx.doi.org/10.1111/ejh.13497 Text en © 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Uyl‐de Groot, Carin A. Ramsden, Rachel Lee, Dawn Boersma, Janneke Zweegman, Sonja Dhanasiri, Sujith Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title_full | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title_fullStr | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title_full_unstemmed | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title_short | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment |
title_sort | lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco‐economic assessment |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590122/ https://www.ncbi.nlm.nih.gov/pubmed/32705720 http://dx.doi.org/10.1111/ejh.13497 |
work_keys_str_mv | AT uyldegrootcarina lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment AT ramsdenrachel lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment AT leedawn lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment AT boersmajanneke lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment AT zweegmansonja lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment AT dhanasirisujith lenalidomideasmaintenancetreatmentforpatientswithmultiplemyelomaafterautologousstemcelltransplantationapharmacoeconomicassessment |